Wolfgang Miesbach/LinkedIn
Apr 23, 2026, 03:17
Wolfgang Miesbach: The Haemophilia A Gene Therapy Story Is Moving from West to China
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”The haemophilia A gene therapy story is not over – it is moving from West to China:
West: BioMarin is withdrawing Roctavian from the global market after failing to divest the product, marking a major commercial retreat from this first‑in‑class AAV5 FVIII gene therapy.
China: GS1191‑0445 (AAV8, liver-directed) continues to advance, with new multi‑year data in 76 adults with severe haemophilia A presented by Dr. Wei Liu at WFH 2026.
- Doses: 2×10¹²–4×10¹² vg/kg
- Mean FVIII:C approximately 45 IU/dL at 2 years (3×10¹² vg/kg)
- ABR reduced by up to 99.4% vs baseline
- Zero spontaneous bleeds over 52 weeks at 3×10¹² and 4×10¹²
- No thrombotic events, no inhibitors; TEAEs mostly grade 1–2 under prophylactic prednisone plus tacrolimus
Durable multi‑year expression and near‑elimination of bleeding remain realistic goals.”
Stay updated with Hemostasis Today.
-
Nov 2, 2026, 22:15Micheline Mambue: A Case of Early Stent Thrombosis Successfully Managed With Repeat Angioplasty
-
Nov 2, 2026, 22:12Annie Bauzon: How the Body Produces Millions of Blood Cells Every Day
-
Nov 2, 2026, 22:11Anna Supernat: Does Leukocyte-Associated RNA Retention Affect Platelet-Based Cancer Classification?
-
Nov 2, 2026, 22:07Aabha Divya: Late Biatrial Thrombosis 31 Years After Heart Transplantation
-
Nov 2, 2026, 22:01Sakditad Saowapa: Anticoagulant Pharmacology and the Pursuit of Effective Therapy With Less Bleeding
-
Nov 2, 2026, 21:55Lucio D’Anna: Can Inflammatory Biomarkers Identify Residual Risk in Atrial Fibrillation?
-
Nov 2, 2026, 21:54Dawood Findakly: VTE Prophylaxis during Pregnancy
-
Nov 2, 2026, 21:52N. Mariana S. Vasquez: Five Rules That Help Identify the Cause of Hemolytic Anemia
-
Nov 2, 2026, 21:52Rob Maloney: Working Together to Strengthen Bleeding Disorders Care in the Dominican Republic